This study is testing a new treatment plan for people with HIV who started therapy early. It involves a combination of vaccines and medications aimed at controlling HIV without needing daily medicine. The vaccines use viruses (chimpanzee adenovirus and poxvirus) to help the immune system fight HIV better. The study also includes special antibodies that help block the virus and a medicine called vesatolimod, which boosts immune response. Participants will be randomly assigned to receive either the treatment or a placebo (a harmless pill) and will stop their usual HIV treatment at certain times to see if the new method works.

• The study lasts up to 110 weeks (about 2 years), with four steps involving treatment and pauses in HIV medicine.
• Participants must attend regular visits and follow specific guidelines, including temporarily stopping their regular HIV treatment.
• Eligibility includes a certain weight and no recent use of certain vaccines or medications.